Efficacy of Nardostachys jatamansi (D.Don) DC in post stroke depression: A randomized, double blind, controlled trial

Muzafar Din Ahmad Bhat, Husain Ahmad
{"title":"Efficacy of Nardostachys jatamansi (D.Don) DC in post stroke depression: A randomized, double blind, controlled trial","authors":"Muzafar Din Ahmad Bhat,&nbsp;Husain Ahmad","doi":"10.1016/j.bbii.2023.100012","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Post-stroke Depression (PSD) is a frequent neuropsychiatric manifestation of high clinical importance as it adversely affects recovery and quality of life, interferes with rehabilitation, and is a significant source of burden to caregivers. Prevalence rates of PSD range from 25% to 79%. The reason for treatment failure in patients of PSD includes the timing of intervention or the side effects of medications. <em>Nardostachys jatamansi</em> (D.Don) DC is commonly used in traditional medicine systems for neuropsychiatric and psychosomatic disorders with the least or no side effects. However, its clinical efficacy in PSD remains unraveled. The study aimed to evaluate the efficacy of <em>Nardostachys jatamansi</em> in PSD.</p></div><div><h3>Methods</h3><p>Present study was a double-blind randomized placebo-controlled trial with 20 patients in each test and control group. Participants were randomly allocated to receive <em>Nardostachys jatamansi</em> 3gms (powder) in the test group or placebo in the control group for six weeks. Participants were asked to follow up fortnightly for the assessment of subjective parameters. Objective parameters (Hamilton Depression Rating Scale (HDRS<sub>17</sub>) score and 36-Item Short Form Survey <strong>(</strong>SF-36) were assessed at baseline and end of the trial.</p></div><div><h3>Results</h3><p>After 6 weeks of treatment, there was a statistically significant reduction in HDRS<sub>17</sub> score and SF-36 (p &lt; 0.001), whereas there was no significant difference in the control group (P = 0.108, and 0.29 respectively). Comparison between baseline and post-treatment scores in the test group showed a positive reduction in all subjective parameters however, in the control group there was no statistically significant change. The intergroup analysis revealed that the reduction in HDRS<sub>17</sub> score and improvement in SF-36 score was statistically significant in the test group than the control group (P &lt; 0.001).</p></div><div><h3>Conclusion</h3><p>The study revealed that the test drug is effective in the management of PSD. There was no adverse effect observed during the trial.</p></div>","PeriodicalId":100197,"journal":{"name":"Brain Behavior and Immunity Integrative","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Brain Behavior and Immunity Integrative","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949834123000119","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background

Post-stroke Depression (PSD) is a frequent neuropsychiatric manifestation of high clinical importance as it adversely affects recovery and quality of life, interferes with rehabilitation, and is a significant source of burden to caregivers. Prevalence rates of PSD range from 25% to 79%. The reason for treatment failure in patients of PSD includes the timing of intervention or the side effects of medications. Nardostachys jatamansi (D.Don) DC is commonly used in traditional medicine systems for neuropsychiatric and psychosomatic disorders with the least or no side effects. However, its clinical efficacy in PSD remains unraveled. The study aimed to evaluate the efficacy of Nardostachys jatamansi in PSD.

Methods

Present study was a double-blind randomized placebo-controlled trial with 20 patients in each test and control group. Participants were randomly allocated to receive Nardostachys jatamansi 3gms (powder) in the test group or placebo in the control group for six weeks. Participants were asked to follow up fortnightly for the assessment of subjective parameters. Objective parameters (Hamilton Depression Rating Scale (HDRS17) score and 36-Item Short Form Survey (SF-36) were assessed at baseline and end of the trial.

Results

After 6 weeks of treatment, there was a statistically significant reduction in HDRS17 score and SF-36 (p < 0.001), whereas there was no significant difference in the control group (P = 0.108, and 0.29 respectively). Comparison between baseline and post-treatment scores in the test group showed a positive reduction in all subjective parameters however, in the control group there was no statistically significant change. The intergroup analysis revealed that the reduction in HDRS17 score and improvement in SF-36 score was statistically significant in the test group than the control group (P < 0.001).

Conclusion

The study revealed that the test drug is effective in the management of PSD. There was no adverse effect observed during the trial.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Nardostachys jatamansi (D.Don) DC治疗脑卒中后抑郁的疗效:一项随机、双盲、对照试验
背景脑卒中后抑郁(PSD)是一种常见的具有高度临床重要性的神经精神表现,因为它对康复和生活质量产生不利影响,干扰康复,并且是护理人员负担的重要来源。PSD的患病率在25%到79%之间。PSD患者治疗失败的原因包括干预时间或药物副作用。Nardostachys jatamansi(D.Don)DC通常用于传统医学系统中治疗神经精神和心身疾病,副作用最小或没有副作用。然而,它在PSD中的临床疗效仍不清楚。本研究旨在评估日本Nardostachys jatamansi治疗帕金森病的疗效。方法本研究是一项双盲随机安慰剂对照试验,每组20名患者。参与者被随机分配接受试验组的Nardostachys jatamansi 3g(粉末)或对照组的安慰剂,为期六周。参与者被要求每两周随访一次,以评估主观参数。在基线和试验结束时评估客观参数(汉密尔顿抑郁量表(HDRS17)评分和36项简式调查(SF-36)。结果治疗6周后,HDRS17评分和SF-36评分均有统计学意义的降低(p<0.001),而对照组无显著差异(p分别为0.108和0.29)。试验组的基线和治疗后评分之间的比较显示,所有主观参数都呈阳性降低,但对照组没有统计学上的显著变化。组间分析显示,试验组HDRS17评分的降低和SF-36评分的改善与对照组相比具有统计学意义(P<;0.001)。试验期间未观察到任何不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
The association between c-reactive protein and human brain microstructure: A systematic review of diffusion imaging studies Pharmacology of natural bioactive compounds used for management of Huntington diseases: An overview Inflammatory biomarker findings from a randomized controlled trial of heated yoga for depression Effect of leech therapy in dermatophytosis: A randomized standard controlled trial Role of plant-derived compounds in immune enhancement against uncontrollable cell proliferation
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1